Skip to main content
. 2018 Jun 13;12:1727–1742. doi: 10.2147/DDDT.S158518

Figure 5.

Figure 5

Axitinib and AB1010 increased COX-2 expression in a dose-dependent manner in tested TCC cells by WB analysis. (A) h-5637 and K9TCC#1Lillie cells were treated with axitinib and AB1010 at doses of 0, 1, 5, and 10 μM for 24 hours. Actin was used as a loading control. Axitinib and AB1010 increased COX-2, but not NF-κB (specific band labeled with arrow) expression in h-5637 cells. AB1010 increased COX-2 and NF-κB protein expression in a dose-dependent manner in K9TCC#1Lillie cells. (B) Densitometry analysis of COX-2 and p-Akt protein bands from WB analysis was performed using VisionWorks analysis software. Values represent the mean ± SE of the measured densitometry of each protein band from three independent experiments. Paired Student’s t-test was used to compare axitinib and AB1010 treatments to controls (*p<0.05, **p<0.01, ***p<0.001).

Abbreviations: COX, cyclooxygenase; WB, Western blot; TCC, transitional cell carcinoma; NF-κB, nuclear factor kappa-light-chain-enhance of activated B cells; Akt, V-akt murine thymoma oncogene homolog 1; p-Akt, phosphorylated Akt; MW, molecular weight; ns, non-specific.